News Sentiment

FBRX sentiment intelligence

Forte Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 61 Balanced news tone 54 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 43.92 Week of 10 Jul 2026

Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

+109.9% over one week, +150.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Forte Biosciences stock hits 52-week high at $45.39

Market Reaction

Price moving ahead of tone

72/100 confidence

Primary event Market update 81/100 classification

One-week reaction 109.9% Price confirming higher

Trend fit Trend inactive 150.1% over four weeks

Fair value 168.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 21

Neutral 31

Negative 2

Relevance

Why the article matched

Direct first

Direct company coverage 46

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Stock Titan 9

Market source 7

TradingView 6

Seeking Alpha 5

Investing.com 4

marketscreener.com 3

TradingKey 3

simplywall.st 3

Event Lens

What the news is about

Classified themes

Market update 31

Earnings 20

Deals and strategy 1

Regulatory and legal 1

Balance sheet 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54

Stock Traders Daily Direct company coverage

(FBRX) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis of Forte Biosciences Inc. (FBRX), highlighting strong sentiment across all horizons and a significant risk-reward setup. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with spe

Tone: Positive 72/100
Event: Market update
Published: 02 Jul 2026 14:12
Source: Stock Traders Daily

TradingView Direct company coverage

Enterprise value to EBIT forward of Forte Biosciences, Inc. – NASDAQ:FBRX

This article provides a specific financial metric, the enterprise value to EBIT forward, for Forte Biosciences, Inc. (NASDAQ: FBRX). It appears to be a stub or a section from a larger financial data platform like TradingView, given the minimal content and the surrounding navigati

Tone: Neutral 50/100
Event: Market update
Published: 30 Jun 2026 19:39
Source: TradingView

marketscreener.com Direct company coverage

Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Growth Benchmark

Forte Biosciences, Inc. (NasdaqCM: FBRX) has been added to the Russell 2000 Growth Benchmark. This move highlights the company's growth trajectory and inclusion in key market indices. Forte Biosciences is a clinical-stage biopharmaceutical company focused on advancing FB102 for a

Tone: Positive 67/100
Event: Market update
Published: 30 Jun 2026 00:12
Source: marketscreener.com

marketscreener.com Direct company coverage

Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Small Cap Comp Growth Benchmark

Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to various Russell Growth benchmarks and indices, highlighting increased visibility for the clinical-stage biopharmaceutical c

Tone: Positive 80/100
Event: Market update
Published: 29 Jun 2026 21:11
Source: marketscreener.com

marketscreener.com Direct company coverage

Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Growth Benchmark Index

Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company is focused on advancing its anti-CD122 monoclonal antibody therapeutic candidate, FB102, for broad autoimmune indications such as celiac disease and no

Tone: Positive 70/100
Event: Market update
Published: 29 Jun 2026 08:13
Source: marketscreener.com

TradingKey Direct company coverage

Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Forte Biosciences Inc (FBRX), reporting a current financial score of 6.67, ranking it 230 out of 389 in the Biotechnology & Medical Research industry. It notes that the company's financial status is robust, though operating efficiency

Tone: Neutral 50/100
Event: Market update
Published: 24 Jun 2026 07:40
Source: TradingKey

Stock Titan Direct company coverage

Forte Biosciences (FBRX) CFO receives 22,000 stock options grant

Forte Biosciences (FBRX) Chief Financial Officer Antony A. Riley was granted 22,000 stock options with an exercise price of $17.15 per share, expiring on June 16, 2036. These compensation-related options will vest monthly over four years, starting June 16, 2026, contingent upon h

Tone: Neutral 50/100
Event: Market update
Published: 17 Jun 2026 20:41
Source: Stock Titan

Stock Titan Direct company coverage

Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner

Forte Biosciences (FBRX) has awarded 500,000 stock options to director and officer Paul A. Wagner. These options have an exercise price of $17.15 per share and expire on June 16, 2036. The award is compensation-related and vests monthly over four years, provided Wagner continues

Tone: Neutral 50/100
Event: Market update
Published: 17 Jun 2026 20:41
Source: Stock Titan

TradingKey Direct company coverage

Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Forte Biosciences Inc (FBRX), listing its major shareholders and institutional holdings as of recent updates. It breaks down the proportion of shares held by various investment entities and provides a historical overview of instit

Tone: Neutral 50/100
Event: Market update
Published: 17 Jun 2026 15:40
Source: TradingKey

TradingKey Direct company coverage

Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

The article provides a technical analysis of Forte Biosciences Inc (FBRX), detailing its current price momentum score as 7.04 and ranking it 156 out of 388 in the Biotechnology & Medical Research industry. It identifies support at $14.38 and resistance at $21.94, suggesting suita

Tone: Negative 39/100
Event: Market update
Published: 17 Jun 2026 05:41
Source: TradingKey